RGEN Stock: Price, Earnings History and SEC Filings
Repligen Corporation (RGEN) last traded at $176.94, down 6.20% on the latest session and down 8.0% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.53 against an analyst estimate of $0.46, a beat of 15.2%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RGEN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 27, 2026 | $0.53 | $0.46 | +15.22% |
| Jun 2026 | Jul 28, 2026 | $0.54 | $0.45 | +20.00% |
| Mar 2026 | May 5, 2026 | $0.48 | $0.38 | +26.32% |
| Dec 2025 | Feb 24, 2026 | $0.49 | $0.44 | +11.36% |
RGEN beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How RGEN reacts to earnings
Across its last 8 earnings releases, RGEN moved 4.5% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-27 | Before open | -2.43% |
| 2026-07-28 | Before open | +10.90% |
| 2026-07-22 | Before open | +2.26% |
| 2026-05-05 | Before open | +6.26% |
| 2026-02-24 | Before open | -0.54% |
| 2025-10-28 | Before open | -5.92% |
| 2025-07-29 | Before open | +4.72% |
| 2025-04-29 | Before open | -2.92% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
RGEN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $738M | $49M | $94M | 6.6% | $0.86 |
| 2024 | $634M | -$26M | $150M | -4.0% | $-0.46 |
| 2023 | $632M | $36M | $78M | 5.6% | $0.63 |
| 2022 | $802M | $186M | $87M | 23.2% | $3.24 |
| 2021 | $671M | $128M | $52M | 19.1% | $2.24 |
| 2020 | $366M | $60M | $40M | 16.4% | $1.11 |
| 2019 | $270M | $21M | $49M | 7.9% | $0.44 |
| 2018 | $194M | $17M | $22M | 8.6% | $0.37 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for RGEN
- 10-Q · Oct 30, 2026
- 8-K · Oct 30, 2026Unregistered share sale, Other events, Financial statements and exhibits
- 8-K · Oct 27, 2026Results of operations, Financial statements and exhibits
- 8-K · Oct 6, 2026Acquisition or disposal completed, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Sep 15, 2026Officer or director change
- 8-K · Sep 8, 2026Other events
- 424B3 · Sep 4, 2026
- 10-Q · Jul 29, 2026
- 8-K · Jul 28, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 22, 2026Material agreement, Results of operations, Regulation FD disclosure
Insider filing activity
RGEN insiders filed 9 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
RGEN news
- RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlookNov 1, 2026 · finance.yahoo.com
- 5 must-read analyst questions from Repligen’s Q3 earnings callOct 31, 2026 · finance.yahoo.com
- Repligen Announces $1 Billion Private Convertible Senior Notes TransactionOct 30, 2026 · finance.yahoo.com
- Repligen prices $1B convertible notes due 2031 to refinance 2028 debtOct 30, 2026 · streetinsider.com
- Repligen Corporation (RGEN) Surges on Revenue Beat and Raised Full-Year Organic OutlookOct 28, 2026 · finance.yahoo.com
- Repligen Corporation (RGEN) Benefits From Biotech Momentum and Strong EarningsOct 28, 2026 · finance.yahoo.com
- Repligen (RGEN) Could Be 12% Undervalued As Record Revenue Lifts GuidanceOct 28, 2026 · finance.yahoo.com
- Record Revenue Outlook Could Be A Game Changer For Repligen (RGEN)Oct 27, 2026 · finance.yahoo.com
About Repligen Corporation
Repligen Corporation (RGEN) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.